MacroGenics, Inc. (MGNX)
NASDAQ: MGNX · Real-Time Price · USD
4.130
+0.050 (1.23%)
At close: Aug 28, 2026, 4:00 PM EDT
4.100
-0.030 (-0.73%)
After-hours: Aug 28, 2026, 7:30 PM EDT
MacroGenics Revenue
MacroGenics had revenue of $32.83M in the quarter ending June 30, 2026, with 377.97% growth. This brings the company's revenue in the last twelve months to $167.67M, up 11.69% year-over-year. In the year 2025, MacroGenics had annual revenue of $149.50M, down -0.31%.
Revenue (ttm)
$167.67M
Revenue Growth
+11.69%
P/S Ratio
1.50
Revenue / Employee
$597,754
Employees
293
Market Cap
263.08M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 149.50M | -462.00K | -0.31% |
| Dec 31, 2024 | 149.96M | 91.21M | 155.26% |
| Dec 31, 2023 | 58.75M | -93.19M | -61.33% |
| Dec 31, 2022 | 151.94M | 74.49M | 96.19% |
| Dec 31, 2021 | 77.45M | -27.44M | -26.16% |
| Dec 31, 2020 | 104.88M | 40.70M | 63.40% |
| Dec 31, 2019 | 64.19M | 4.07M | 6.76% |
| Dec 31, 2018 | 60.12M | -97.62M | -61.89% |
| Dec 31, 2017 | 157.74M | 65.86M | 71.68% |
| Dec 31, 2016 | 91.88M | -8.97M | -8.90% |
| Dec 31, 2015 | 100.85M | 53.06M | 111.00% |
| Dec 31, 2014 | 47.80M | -10.24M | -17.64% |
| Dec 31, 2013 | 58.04M | -5.79M | -9.07% |
| Dec 31, 2012 | 63.83M | 6.62M | 11.57% |
| Dec 31, 2011 | 57.21M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Niagen Bioscience | 129.08M |
| Compugen | 74.00M |
| Cellectis | 63.82M |
| Invivyd | 58.37M |
| AC Immune | 21.67M |
| Alector | 13.86M |
| Adagene | 9.29M |
| Entrada Therapeutics | 4.69M |
MGNX News
- 12 days ago - MacroGenics price target raised to $11 from $9 at B. Riley - TheFly
- 13 days ago - MacroGenics reports Q2 EPS 31c, consensus 26c - TheFly
- 16 days ago - MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position - GlobeNewsWire
- 16 days ago - MacroGenics Earnings release: Q2 2026 - Filings
- 16 days ago - MacroGenics Quarterly report: Q2 2026 - Filings
- 16 days ago - MacroGenics Slides: Corporate presentation - Filings
- 18 days ago - MacroGenics Announces Achievement of $10 Million Milestone Following Gilead's Exercise of Option to License Preclinical Bispecific Program - GlobeNewsWire
- 5 weeks ago - MacroGenics provides update on MGC026 study - TheFly